TAFFA N TMUSNIWIN TUSNANIN

2017 Position Statement on the Use of Follow-On Biologics and Biosimilars for Endocrine Diseases

American Association of Clinical EndocrinologyTasleḍt n tfeggagin d ssker2017Asuffeɣ unṣib

Agzul n yisemli ASEM

Official American Association of Clinical Endocrinology document (2017) on “2017 Position Statement on the Use of Follow-On Biologics and Biosimilars for Endocrine Diseases”. This position statement provides guidance on follow-on biologics versus biosimilars, interchangeability and substitution, FDA draft guidance for interchangeability of biosimilars, and clinical application. DOI: 10.4158/EP-2017-0052.

Agzul-a ad k-yefk tallalt deg unadi ɣef uttaft. I wellihen klinik, ẓer yal tikkelt lqem unṣib amiran akked uzemz n uleqqem-is.

Isemli unṣib